Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: dividing (101), separating (322)

Nivolumab 480mg (renal)

Description: Chemotherapy Protocol RENAL CELL CANCER Nivolumab (480mg-28 days) Regimen • Renal Cell – Nivolumab (480mg-28 days) Indication • Nivolumab is recommended, within
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Nivolumab-480mg.pdf

Nivolumab 240mg (renal)

Description: Chemotherapy Protocol RENAL CELL CANCER Nivolumab (240mg-14 days) Regimen • Renal Cell – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended, within
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Nivolumab-240mg.pdf

Pembrolizumab_400mg (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Pembrolizumab (400mg) Regimen • Lymphoma – Pembrolizumab (400mg) Indication • Pembrolizumab is indicated for relapsed or refractory classical Hodgkin lymphoma in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Pembrolizumab-400mg.pdf

Pembrolizumab_200mg (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Pembrolizumab (200mg) Regimen • Lymphoma – Pembrolizumab (200mg) Indication • Pembrolizumab is indicated for relapsed or refractory classical Hodgkin lymphoma in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Pembrolizumab-200mg.pdf

Nivolumab (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Nivolumab Regimen • Lymphoma – Nivolumab Indication • Nivolumab is recommended as an option for treating relapsed or refractory classical Hodgkin
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Nivolumab.pdf

Nivolumab 240mg (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Nivolumab (240mg-14 days) Regimen • Lymphoma – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended as an option for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Nivolumab-240mg.pdf

Pembrolizumab_400mg skin

Description: Chemotherapy Protocol SKIN CANCER Pembrolizumab (400mg) Regimen • Skin – Pembrolizumab (400mg) Indication • Pembrolizumab is recommended; - as an option for treating adults with
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Pembrolizumab-400mg.pdf

Pembrolizumab_200mg skin

Description: Regimen Chemotherapy Protocol SKIN CANCER Pembrolizumab (200mg) • Skin – Pembrolizumab (200mg) Indication • Pembrolizumab is recommended; - as an option for treating adults with
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Pembrolizumab-200mg.pdf

Pembrolizumab Ver 1 skin

Description: Chemotherapy Protocol SKIN CANCER Pembrolizumab Pembrolizumab is currently available on a compassionate use basis only – not yet licensed in the UK
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinPembrolizumabVer1.pdf

Nivolumab Ver 1.1 skin

Description: Chemotherapy Protocol SKIN CANCER Nivolumab This regimen may require funding. Regimen Skin – Nivolumab Indication The treatment of advanced (unresectable or metastatic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/NivolumabVer1.1.pdf

21 to 30 of 89

Previous 1 2 3 4 5 … Next